We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
OCT has successfully initiated patient recruitment for phase III clinical trials in hemorrhoids.
Within the project OCT will be running two studies: one with the suppository therapy, and the other where the subjects will undergo a rectal cream treatment. As of now, first subjects have been enrolled in both trials.
The treatment period for both studies is 14 days. The recruitment target for the first study is 120 female and male patients older than 18 years old. The plan is to enroll 192 patients in the cream treatment study.
These are multicenter, randomized phase III studies, the primary goal of which is to evaluate the efficacy of the study medicine vs. active comparator.
Within this project, the OCT team is responsible for a range of services including site selection, project management, data management, clinical and medical monitoring and final report preparation.
July 15, 2019
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
